Characterization of a novel anti-human TNF-alpha murine monoclonal antibody with high binding affinity and neutralizing activity.
- Author:
Moo Young SONG
1
;
Sang Koo PARK
;
Chang Suk KIM
;
Tae Hyoung YOO
;
Bongtae KIM
;
Min Soo KIM
;
Yong Sung KIM
;
Won Jae KWAG
;
Byung Kyu LEE
;
Kwanghee BAEK
Author Information
- Publication Type:Original Article
- Keywords: antibodies, monoclonal; antibody affinity; antibody specificity; tumor necrosis factor-alpha
- MeSH: Amino Acid Sequence; Animals; Antibodies, Monoclonal/chemistry/genetics/*immunology; Antibody Affinity/*immunology; Antibody Specificity; Base Sequence; Blotting, Western; Cell Line; Cytotoxicity, Immunologic; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin Variable Region/genetics; Kinetics; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neutralization Tests; Sequence Analysis, Protein; Tumor Necrosis Factor-alpha/*immunology
- From:Experimental & Molecular Medicine 2008;40(1):35-42
- CountryRepublic of Korea
- Language:English
- Abstract: In order to develop an anti-human TNF-alpha mAb, mice were immunized with recombinant human TNF-alpha. A murine mAb, TSK114, which showed the highest binding activity for human TNF-alpha was selected and characterized. TSK114 specifically bound to human TNF-alpha without cross-reactivity with the homologous murine TNF-alpha and human TNF-beta TSK114 was found to be of IgG1 isotype with kappa light chain. The nucleotide sequences of the variable regions of TSK114 heavy and light chains were determined and analyzed for the usage of gene families for the variable (V), diversity (D), and joining (J) segments. Kinetic analysis of TSK114 binding to human TNF-alpha by surface plasmon resonance technique revealed a binding affinity (KD) of ~5.3 pM, which is about 1,000- and 100-fold higher than those of clinically relevant infliximab (Remicade) and adalimumab (Humira) mAbs, respectively. TSK114 neutralized human TNF-alpha-mediated cytotoxicity in proportion to the concentration, exhibiting about 4-fold greater efficiency than those of infliximab and adalimumab in WEHI 164 cells used as an in vitro model system. These results suggest that TSK114 has the potential to be developed into a therapeutic TNF-alpha-neutralizing antibody with picomolar affinity.
